InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
Cybin (NYSE American: CYBN) (NEO: CYBN) announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003, a next-generation psychedelic-based therapy for major depressive disorder (MDD). The APPROACH study, part of Cybin’s PARADIGM program, is expected to grow to approximately 45 sites. By leveraging site-specific expertise through these SPAs, Cybin aims to enhance protocol…